Much debate exists within the literature with respect to the variant of neovascular agerelated macular degeneration (AMD) known as retinal angiomatous proliferation (RAP). We prefer the term retinal anastomosis to the lesion (RAL), as we believe that the choroidal neovascularization (CNV) lesion precedes the development of an anastomosing retinal vessel to this lesion. Natural history data surrounding RAP lesions are available through analysis of the eyes with subfoveal occult CNV within the placebo arm of the Verteporfin in Photodynamic Therapy (VIP) trial. Although many reports ascribe a poor prognosis to RAP lesions, the data suggest that the true natural history of RAP lesion may be highly variable and similar to that of other CNV lesions. Information from clinical trials suggests that the response of RAP lesions to CNV treatments may also be similar to that of other variants of neovascular AMD.
Introduction
The variant of neovascular age-related macular degeneration (AMD), known as retinal angiomatous proliferation (RAP), represents an estimated 10-12% of newly diagnosed neovascular AMD lesions. 1, 2 Multiple terms have been used to describe these lesions including 'deep retinal vascular anomalous complex' and 'retinal-choroidal anastomosis'. 1, 3 Don Gass proposed a classification scheme that stratifies neovascularization with respect to its physical relationship to the retinal pigment epithelium (RPE). 4 Type 1 neovascularization describes fibrovascular tissue that is posterior to the RPE, whereas Type 2 neovascularization refers to a fibrovascular complex that lies anterior to the RPE. Freund has proposed modifying the original Gass classification to add Type 3 neovascularization to refer to intraretinal neovascularization, as is suspected to occur in these RAP lesions. 5, 6 Yannuzzi et al. introduced the term 'retinal angiomatous proliferation' to describe a vascular process that these authors believe originates within the neurosensory retina, beginning with capillary proliferation, formation of intraretinal neovascularization, and retinal-retinal anastamoses. This retinal neovascularization then extends beneath the neurosensory retina to become subretinal neovascularization (SRN). With time, the SRN may merge with the choroidal circulation beneath the RPE to form retinal-choroidal anastomosis. 7 However, the vasogenic sequence of RAP lesions remains controversial. In contrast to the hypothesis offered by the Yannuzzi et al. we believe, as did Gass, 8 that choroidal neovascularization (CNV) is the initiating event of a RAP lesion rather than retinal neovascularization. Typically, this lesion begins as an occult CNV lesion without a classic component that is then followed by a retinal vessel diving posteriorly into the lesion and communicating with the CNV lesion within the subretinal space. For this reason, we prefer to refer to this entity as 'retinal anastomosis to the lesion' or RAL. For simplicity and consistency, however, we will refer to this condition as 'RAP' throughout this manuscript.
Just as the origin of RAP lesions remains controversial, so does its natural history. RAP lesions have been characterized in the literature as having a poor natural history, Is the natural history truly distinct from other neovascular AMD presentations? It is also unclear whether these statements refer to vision outcomes, anatomic outcomes, or both. Another recurring theme within the literature reporting on RAP lesions is that these lesions do not respond well to treatment, and that no definite therapy has been shown to be beneficial at reducing visual loss and controlling the lesion. This has led to the use of a variety of treatment modalities for these lesions, with the list of therapies resembling those that have been used for any AMD-related CNV lesion, including direct laser photocoagulation, transpupillary thermotherapy, surgical removal of the lesion, surgical excision of the retinal feeder vessels, photodynamic therapy (PDT) guided by fluorescein or indocyanine green (ICG) dye with and without intravitreal triamincolone, periocular anecortave acetate, antivascular endothelial growth factor (VEGF) regimens with pegaptanib sodium (EyeTech Pharmaceuticals, New York, USA), ranibizumab (Lucentis, Genentech Inc, South San Francisco, CA, USA), or bevacizumab (Avastin, Genentech Inc., South San Francisco, CA, USA), or various combinations of the above. 10 Within this review, we will explore the data surrounding the natural history of RAP and what we have learned about how this condition responds to treatment.
Natural history of RAP lesions
The prospective data on the natural history of RAP lesions can be found within one of the phase III trials evaluating PDT, the Verteporfin in Photodynamic Therapy (VIP) trial (Visudyne, Novartis Pharma AG, Basel, Switzerland). 11 This was a double-masked, placebo-controlled, randomized, multicenter clinical trial that enrolled adults with a minimum age of 50 years, who had subfoveal CNV from AMD. Of the 339 eyes studied in the VIP study, roughly 75% (258/339) had subfoveal occult lesions without evidence of classic CNV. These individuals were required to have entry vision of at least 20/100, lesion size of up to 9 disc areas (DAs), and evidence of recent disease progression. Recent disease progression was considered to be present if any of the following was true: (1) blood associated with the CNV lesion was present, (2) vision loss of at least one line of acuity had occurred in the presence of known CNV, or (3) at least a 10% growth in the greatest linear diameter of the lesion had occurred within 3 months of study entry. 11 The presence of RAP was not an exclusion criterion for VIP study participation.
After reporting the VIP trial results, the baseline stereoscopic film-based colour fundus photographs and fluorescein angiograms were reviewed by the Wilmer Reading Center for the presence or absence of RAP. The reading center graders remained masked to all vision and anatomic outcomes when making this determination. Eyes were considered to have a RAP lesion if either of the two following criteria was met: (1) a retinal vessel extended at a right angle from the inner retina towards the RPE anterior to a CNV lesion (Figure 1 ), or (2) a single intraretinal haemorrhage or a cluster of intraretinal haemorrhages were present overlying a retinal vessel, which itself was directly anterior to CNV ( Figure 2 ). ICG angiography was not used to identify RAP lesions within this study.
To address the questions surrounding the natural history of RAP, we will examine vision outcomes in the subgroup of VIP participants who had RAP and were assigned to the placebo arm of the trial, and we will compare this group with the remaining natural history eyes that did not have RAP at study entry. Overall, 10% (27/258) of the VIP study eyes with occult CNV lesions were categorized as RAP lesions, with approximately equal representation of RAP lesions in both the PDT and natural history arms of the trial (10% (17/166) vs 11% (10/92), respectively). Although only 10 eyes in the natural history group had RAP lesions, the data collected on these individuals were prospective, followed standardized methods, and were complete through 24 months; hence, it provides meaningful information that cannot be found elsewhere, while also offering the concurrently enrolled comparison groups of natural history eyes without RAP and eyes with RAP treated with PDT. lesions in general, which may imply that they have greater potential for further growth. In terms of presenting level of visual acuity, vision was categorized into two strata: the better level of vision included those with vision of 20/20 through to 20/50, whereas the lower vision group were those with 20/50 through to 20/100 visual acuity. The majority of the RAP eyes were in the lower vision strata (78%) at presentation, relative to 50% of the eyes without RAP. This observation is consistent with the clinical impression shared by many authors that RAP lesions have a more ominous course. Table 2 summarizes several visual acuity outcomes at the 24-month visit in the VIP trial, such as, vision loss of three or more lines of acuity, vision loss of at least six lines of acuity, visual acuity of 20/200 or worse, and mean change in visual acuity from baseline. In three of these four analyses, the natural course for occult CNV lesions without a classic component with RAP appears very similar to similar lesions without RAP. Note that mean visual acuity loss was À5.3 lines in RAP eyes as compared with À5.1 lines in non-RAP CNV eyes at 24 months. Although there was one analysis in which eyes without RAP had a better natural history (vision loss of at least three lines of acuity), the totality of the evidence would suggest that there is no dramatic difference in the natural history of eyes with RAP compared with those without.
Do eyes with RAP lesions respond differently to treatment for CNV?
Another controversy surrounding RAP lesions is whether or not they favourably respond to treatment. As an example, Bottoni et al. reported that no information from the VIP trial is available that describes the use of PDT for the treatment of RAP lesions, and they referenced an abstract that reported that PDT is of little benefit in these lesions.
13,14 Table 3 shows 2-year vision outcomes of the VIP trial participants with occult lesions without a classic component by treatment assignment (PDT vs sham), subgrouped by the presence or absence of RAP. For each visual acuity outcome, RAP lesions treated with PDT always fared better than eyes with RAP lesions assigned to the sham arm. The same is true for occult lesions without 
Summary of lessons learned from VIP trial with respect to RAP lesions
The 10% prevalence of RAP among VIP trial participants was consistent with the reported estimates of the prevalence of this AMD variant. Prospective data on the natural history of these lesions did not identify any dramatic difference in outcomes for these eyes compared with similar eyes without RAP; although we cannot completely rule out a small interaction effect. A similar proportion of eyes with RAP, as compared with eyes without RAP, were assigned to each of the treatment groups such that comparisons of PDT treatment efficacy could be evaluated with reference to the presence of RAP. Vision outcomes with PDT did not seem to be influenced by the presence of RAP, and eyes with RAP treated with PDT did better than eyes allocated to the sham group. Thus, review of the VIP trial data dispels several myths about eyes with RAP. 15 Do other data corroborate the VIP experience?
There are very few reports on the natural history of RAP lesions. A recent study characterized 16 eyes with RAP lesions that were observed for a variable length of time from 6 to 44 months. 16 Mean visual acuity at presentation was 20/50 in this cohort and which then fell to 20/80 at the month 6 exam. Mean visual acuity at the last followup visit measured 20/100. Although there is no comparison group and the final visit covered a broad range for the duration of follow-up, these observations are not strikingly dissimilar from a typical neovascular AMD cohort. We know from earlier studies that lesion composition of AMD-associated CNV lesions affects the natural course. Generally speaking, eyes with occult lesions without a classic component (which reflects the majority of lesions that have RAP) can have quite a variable visual prognosis, and from this description, CNV with a retinal anastomosis to the CNV lesion appears to be no exception.
Is Anti-VEGF therapy recommended for RAP lesions?
Several recent reports suggest that anti-VEGF therapy is a promising treatment modality for eyes with RAP lesions. Given that anti-VEGF therapy has become the standard of care for the majority of neovascular AMD lesions, it comes as no surprise that various groups would evaluate their experience with either ranibizumab or bevacizumab for eyes with RAP lesions. In addition, there is a plausible biological rationale to pursue anti-VEGF treatments for these lesions. Case-control studies of eyes with RAP lesions showed both early and late reductions in choroidal filling using ICG angiography in the eyes with RAP. This choroidal circulatory disturbance may in turn lead to hypoxia in the outer retina that may subsequently upregulate angiogenic growth factors such as VEGF. 17 In addition, a recent immunohistochemical study identified VEGF in a RAP lesion from a cadaver eye. 18 Several small retrospective studies have described short-term results managing RAP lesions with bevacizumab. 10, 19, 20 Each of these groups report stabilization or improvement of visual acuity in eyes with RAP lesions for a period of up to 3 months after initiation of intravitreal bevacizumab. Recently, Gharbiya et al. 21 reported 12-month outcomes in a previously treatment-naive cohort of 17 eyes followed prospectively while being managed with bevacizumab as a monotherapy. Each study eye received a monthly treatment of three doses followed by a 'prn' or as needed, regimen of re-treatment at each of the monthly visits through to month 12. Vision results were positive, with mean baseline ETDRS letter score rising from 40 letters (Snellen equivalent B20/42) to 48 letters (Snellen equivalent B20/28) at 12 months. In fact, three eyes, or 18%, improved at least by 15 letters. Substantial reductions in optical coherence tomography (OCT) 21 These results are consistent with expectations, given that RAP is a variant of neovascular AMD, and it is very likely that RAP lesions were included in all the phase III studies evaluating ranibizumab for neovascular AMD. Once again, these data also refute the notion that RAP lesions may respond less well to the treatment when compared with other neovascular lesions.
Other groups of investigators have shared their positive experience using ranibizumab monotherapy for neovascular AMD lesions with RAP. 22, 23 A retrospective study describing 31 RAP lesions (some of which had received earlier PDT), managed with ranibizumab following a strictly prn regimen, reported outcomes 10-22 months after treatment initiation. During this variable length of follow-up, the average number of ranibizumab treatments was 5 (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Comparison of the mean visual acuity at baseline and the mean visual acuity at the final visit for each patient suggested vision improvement (20/100 vs 20/63). Concomitant reductions in OCT-measured retinal thickness and cessation in fluorescein angiographic leakage were also apparent. 23 As clinicians have been exploring combination therapies to address all forms of neovascular AMD, the same type of experimentation has been occurring in eyes with RAP lesions. The driving rationale to investigate combination therapy is to combine different mechanisms of action to stop the angiogenic sequence, and by doing so, to increase the efficiency of the treatment, as manifested by reduced treatment burden and maintenance of superior vision outcomes. A recent 9-month pilot study of eight treatment-naive RAP lesions, managed with a single application of ICG-guided PDT combined with monthly intravitreal bevacizumab for 3 months followed by a PRONTO style prn regimen 24 with bevacizumab only thereafter, found favourable vision outcomes. 25 Most of these eyes received the required three intravitreal injections and then required no further bevacizumab. Mean visual acuity improved from 20/100 to about 20/50, as 5 of 8 eyes gained at least 3 lines of acuity. Retinal thickness, as indicated on OCT, decreased from 372 mm to 162 mm during follow-up. Whether the benefit seen here is solely due to the bevacizumab or is attributed to the combination effects of bevacizumab plus PDT remains unknown. Thus far, limited information exists to compare combination treatment regimens with monotherapy regimens using anti-VEGF agents alone. In a limited prospective study of 37 eyes randomly assigned to ranibizumab monotherapy, PDT plus ranibizumab, or PDT plus intravitreal injection of 4 mg triamcinolone, no difference in visual outcomes was noted at month 6, with most study eyes avoiding vision loss. However, this study had several limitations, including small numbers of participants within each treatment group, nonstandard Snellen visual acuities, and lack of masking of treatment assignment. 26 
Summary
'Retinal angiomatous proliferation' is a variant of neovascular AMD with a distinct clinical appearance. Multiple names have been used to describe this entity. In the absence of sequential histopathological specimens showing the evolution of RAP lesions, the debate will continue as to the origin of these lesions. Information from clinical trials suggests that the natural history of these lesions and their response to various CNV treatments may be similar to typical neovascular AMD lesions without a RAP component.
